`Ramstack et al.
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 6,667,061 B2
`*Dec. 23, 2003
`
`US006667061B2
`
`(54) PREPARATION OF INJECTABLE
`SUSPENSIONS HAVING IMPROVED
`INJECTABILITY
`
`(75) Inventors: J. Michael Ramstack, Lebanon, OH
`(US); M. Gary I. Riley, Cambridge,
`.
`MA(US); Stephen E- Zale’ HOPkmtPH’
`MA (Us); Joyce M- Hotl, Clnclnnath
`OH (US); Olufunmi L- Johnson,
`Cambridge, MA (US)
`
`(73) Assignee: Alkermes Controlled Therapeutics,
`Inc., Cambridge, MA (US)
`
`5,656,299 A * 8/1997 Kino et al. ............... .. 424/489
`5,658,593 A
`8/1997 Orly et 91
`5,667,808 A
`9/1997 Johnson et 81.
`5,688,801 A 11/1997 Mesens et al.
`5’747’058 A
`5/1998 Tlpton et al'
`2
`$4.656“ 6‘ ‘11'
`,
`,
`ickey et al.
`5,871,778 A
`2/1999 Kino et 81.
`5,916,598 A
`6/1999 Rickey et 81.
`5,942,253 A
`8/1999 GoInbotZ et 81.
`5,965,168 A 10/1999 Mesens et 81.
`6,495,164 B1 * 12/2002 Ramstack et al. ........ .. 424/489
`
`FOREIGN PATENT DOCUMENTS
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`
`EP
`
`0 486 959 A1
`
`5/1992
`
`
`
`patent is extended or adjusted under 35 U-S-C- 154(k)) by 0 days-
`
`This patent is subject to a terminal dis-
`claimer.
`
`.
`(21) Appl' NO" 10/259’949
`(22) Filed;
`Sep_ 30, 2002
`
`(65)
`
`Prior Publication Data
`
`
`
`
`
`W0 {E50 WO IB-WO 90/13361
`
`11/1990
`
`5/1994
`WO IB-WO 94/10982
`W0 1B_WO 94/25460 A1 11/1994
`WO IB-WO 95/13799
`5/1995
`WO IB-WO 96/01652 A1
`1/1996
`WO IB-WO 96/40049
`12/1996
`WO IB-WO 97/41837
`11/1997
`WO IB-WO 97/44039 A1 11/1997
`WO IB-WO 99/12549
`3/1999
`WO IB-WO 99/25354 A2
`5/1999
`
`US 2003/0113380 A1 Jun. 19, 2003
`
`OTHER PUBLICATIONS
`
`Related US. Application Data
`
`(63) Continuation of application No_ 09/577,875’ ?led on May
`25, 2000, now Pat. No. 6,495,164.
`(51) Int. Cl.7 .......................... .. A61K 9/14; A61K 9/08;
`
`(52) US. Cl. ..................... .. 424/489; 424/490; 424/497;
`
`(58) Field of Search ............................... .. 424/489, 422,
`424/490, 497, 486, 484, 494
`
`(56)
`
`References Cited
`
`4,530,840 A
`
`US. PATENT DOCUMENTS
`3,523,906 A
`8/1970 Vrancken et al.
`3,691,090 A
`9/1972 Kitajima et al.
`3700215 A 10/1972 Hardmim et a1‘
`2
`gtesl'al'
`3:891:570 A
`6/1975 Fukushima et a1‘
`3,960,757 A
`6/1976 Morishita et al.
`4,221,862 A
`9/1980 Naito et al.
`4,384,975 A
`5/1983 Fong
`4389330 A
`6/1983 Tlce et a1‘
`4,818,517 A
`4/1989 Kwee et a1‘
`4,940,588 A
`7/199O Sparks et aL
`5,066,436 A 11/1991 Komen et a1_
`5,385,738 A
`1/1995 Yamahira et a1_
`5,407,609 A
`4/1995 Tice et al.
`5,428,024 A
`6/1995 Chu et a1.
`5,478,564 A 12/1995 Wantief et a1~
`5,541,172 A
`7/1996 Labric et ‘11'
`2
`geriesrtlscitgl'al
`5:654jOO8 A
`8/1997 Herbert et a1‘ '
`5,654,010 A
`8/1997 Johnson et 81.
`5,656,297 A
`8/1997 Bernstein et a1.
`
`7/1985 Tice et al.
`
`_
`_
`Akers, M.J. et al., “Formulation Design and Development of
`Parenteral Suspensions,” Journal of Parenteral Science and
`Technology, 41(3):88—95 (May—Jun. 1987).
`Beck, L.R. et al., Biology of Reproduction, 28:186—195
`(Feb. 1983).
`Bodmeier, R' et all‘, International Journal of Pharmaceuti_
`
`_
`_
`_
`_
`_
`_
`Cajavec, Stamslav et al., “The primary chicken vaccination
`against Newcastle disease With antigenic virus subunits
`prepared in a Water—in—oil—in—Water emulsion,” Periodicum
`Biologorum, 99(1):39—44 (1997).
`
`(Llst Con?rmed on next Page")
`
`Primary Examiner—Thurman K. Page
`.
`Assistant Examiner—Rachel M. Bennett
`(74)~Att0rney, Agent, or Firm—Andrea G. Reister;
`Covmgton & Burhng
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`ABSTRACT
`(57)
`Injectable compositions having improved injectability. The
`mjectable compositions include microparticles suspended in
`an aqueous injection vehicle having a viscosity of at least 20
`cp at 20° C. The increased viscosity of the injection vehicle
`that constitutes the ?uid phase of the suspension signi?
`cantly reduces in vivo injectability failures. The injectable
`compositions can be made by mixing dry microparticles
`With an aqueous injection vehicle to form a suspension, and
`then mixing the suspension With a viscosity enhancing agent
`to increase the viscosity of the ?uid phase of the suspension
`to the desired level for improved injectability.
`
`23 Claims, No Drawings
`
`LUYE1001
`IPR of Patent No. 6,667,061
`
`
`
`US 6,667,061 B2
`Page 2
`
`OTHER PUBLICATIONS
`
`Cha, Y and Pitt, C.G., “The Acceleration of Degradation—
`Controlled Drug Delivery frorn Polyester Microspheres,”
`Journal of Controlled Release, 8:259—265 (1989).
`Cha, Y. and Pitt, C.G., “A One—Week Subderrnal Delivery
`System for L—Methadone Based on Biodegradable Micro
`particles,” Journal of Controlled Release, 7:69—78 (1988).
`“HoW to Avoid Clogging of Insulin Syringes,” Diabetes
`Forcase, pp. 27—29 (Nov.—Dec. 1976).
`Jalil, R. et al., Journal of Microencapsulation 7(3):297—319
`(Jul.—Sep. 1990).
`Li, Wen—I et al., Journal of Controlled Release, 37:199—214
`(Dec. 1995).
`Maulding, H.V. et al., “Biodegradable Microparticles:
`Acceleration of Polyrneric EXcipient Hydrolytic Rate by
`Incorporation of a Basic Medicarnent,” Journal of Conrolled
`Release, 3:103—117 (Mar. 1986).
`
`Pharmaceutical Dosage Forrns Disperse Systerns, edited by
`Herbert A. Lieberrnan, Martin M. Rieger, Gilbert I. Bank,
`second edition, Chapter 7, “Injectable Ernulsions and Sus
`pensions,” 1:261—318.
`Pharrnaceutical Dosage forrns Disperse Systerns, edited by
`Herbert A. Lieberrnan, Martin M. Rieger, Gilbert I. Bank,
`second edition, Chapter 7, “Viscosity—Irnpairing Agents in
`Disperse Systerns,” 2:287—313 (1996).
`Sah, Hongkee et al., Pharmaceutical Research, 13:360—367
`(Mar. 1996).
`Sato, Toyorni et al., Pharmaceutical Research, 5:21—30
`(1988).
`Zingerrnan, JR. et al., “Autornatic injector apparatus for
`studying injectability of parenteral formulations for animal
`health,”
`International
`Journal
`of
`Pharrnaceuticals,
`36:141—145 (1987).
`* cited by eXarniner
`
`LUYE1001
`IPR of Patent No. 6,667,061
`
`
`
`US 6,667,061 B2
`
`1
`PREPARATION OF INJECTABLE
`SUSPENSIONS HAVING IMPROVED
`INJECTABILITY
`
`This application is a continuation of Ser. No. 09/577,875,
`?led May 25, 2000, now US. Pat. No. 6,495,164.
`
`BACKGROUND OF THE INVENTION
`
`1. Field of the Invention
`The present invention relates to preparation of injectable
`compositions. More particularly, the present invention
`relates to injectable suspensions having improved
`injectability, and to methods for the preparation of such
`injectable suspensions.
`2. Related Art
`Injectable suspensions are heterogeneous systems that
`typically consist of a solid phase dispersed in a liquid phase,
`the liquid phase being aqueous or nonaqueous. To be effec
`tive and pharmaceutically acceptable, inj ectable suspensions
`should preferably be: sterile; stable; resuspendable; syringe
`able; injectable; isotonic; and nonirritating. The foregoing
`characteristics result in manufacturing, storage, and usage
`requirements that make injectable suspensions one of the
`most difficult dosage forms to develop.
`Injectable suspensions are parenteral compositions in that
`they are introduced into an organism or host by means other
`than through the gastrointestinal tract. Particularly, inject
`able suspensions are introduced into a host by subcutaneous
`(SC) or intramuscular (IM) injection. Injectable suspensions
`may be formulated as a ready-to-use injection or require a
`reconstitution step prior to use. Injectable suspensions typi
`cally contain betWeen 0.5% and 5.0% solids, With a particle
`siZe of less than 5 pm for IM or SC administration.
`Parenteral suspensions are frequently administered through
`needles about one-half to tWo inches long, 19 to 22 gauge,
`With an internal diameter in the range of 700 to 400 microns,
`respectively.
`To develop an effective and pharmaceutically acceptable
`injectable suspension, a number of characteristics must be
`evaluated. These characteristics include syringeability,
`injectability, clogging, resuspendability, and viscosity. As
`Will be readily apparent to one skilled in the art, other
`characteristics and factors should be considered in develop
`ing an injectable suspension (see, for example, Floyd, A. G.
`and Jain, S., Injectable Emulsions and Suspensions, Chapter
`7 in Pharmaceutical Dosage Forms: Disperse Systems Vol.
`2, Edited by Lieberman, H. A., Rieger, M. M., and Banker,
`G. S., Marcel Dekker, NeW York (1996), the entirety of
`Which is incorporated herein by reference and referred to
`herein as “the Floyd et al. Chapter”).
`Syringeability describes the ability of an injectable sus
`pension to pass easily through a hypodermic needle on
`transfer from a vial prior to injection. It includes character
`istics such as ease of WithdraWal, clogging and foaming
`tendencies, and accuracy of dose measurements. As
`described in the Floyd et al. Chapter, increase in the
`viscosity, density, particle siZe, and concentration of solids
`in suspension hinders the syringeability of suspensions.
`Injectability refers to the performance of the suspension
`during injection. Injectability includes factors such as pres
`sure or force required for injection, evenness of 110W, aspi
`ration qualities, and freedom from clogging.
`Clogging refers to the blockage of syringe needles While
`administering a suspension. It may occur because of a single
`large particle, or an aggregate that blocks the lumen of the
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`55
`
`60
`
`65
`
`2
`needle due to a bridging effect of the particles. Clogging at
`or near the needle end may be caused by restrictions to flow
`from the suspension. This may involve a number of factors,
`such as the injection vehicle, Wetting of particles, particle
`siZe and distribution, particle shape, viscosity, and flow
`characteristics of the suspension.
`Resuspendability describes the ability of the suspension
`to uniformly disperse With minimal shaking after it has stood
`for some time. Resuspendability can be a problem for
`suspensions that undergo “caking” upon standing due to
`settling of the de?occulated particles. “Caking” refers to a
`process by Which the particles undergo groWth and fusion to
`form a nondispersible mass of material.
`Viscosity describes the resistance that a liquid system
`offers to flow when it is subjected to an applied shear stress.
`A more viscous system requires greater force or stress to
`make it flow at the same rate as a less viscous system. A
`liquid system Will exhibit either NeWtonian or non
`NeWtonian ?oW based on a linear or a non-linear increase,
`respectively, in the rate of shear With the shearing stress.
`Structured vehicles used in suspensions exhibit non
`NeWtonian How and are typically plastic, pseudoplastic, or
`shear-thinning With some thixotropy (exhibiting a decrease
`in viscosity With an increase in the rate of shear).
`In design of injection vehicles, viscosity enhancers are
`added in order to retard settling of the particles in the vial
`and syringe. HoWever, viscosity is typically kept loW, in
`order to facilitate mixing, resuspension of the particles With
`the vehicle, and to make the suspension easier to inject (i.e.,
`loW force on the syringe plunger). For example, Lupron
`Depot from TAP Pharmaceuticals (mean particle siZe of
`approximately 8 pm) utiliZes an injection vehicle With a
`viscosity of approximately 5.4 cp. The ?uid phase of a
`suspension of Decapeptyl from DebioPharm (mean particle
`siZe of approximately 40 pm), When prepared as directed,
`has a viscosity of approximately 19.7 cp. Conventional
`parenteral suspensions are dilute, With limitations for vis
`cosity because of syringeability and injectability constraints.
`See, for example, the Floyd, et al. Chapter noted above.
`Injectable compositions containing microparticle prepa
`rations are particularly susceptible to injectability problems.
`Microparticle suspensions may contain 10—15% solids, as
`compared With 0.5—5% solids in other types of injectable
`suspensions. Microparticles, particularly controlled release
`microparticles containing an active agent or other type of
`substance to be released, range in siZe up to about 250 pm,
`as compared With a particle siZe of less than 5 pm recom
`mended for IM or SC administration. The higher concen
`tration of solids, as Well as the larger solid particle siZe,
`make it more difficult to successfully inject microparticle
`suspensions. This is particularly true since it is also desired
`to inject the microparticle suspensions using as small a
`needle as possible to minimiZe patient discomfort.
`Thus, there is a need in the art for an injectable compo
`sition With improved injectability. There is a particular need
`in the art for an injectable composition that solves the
`injectability problems associated With microparticle suspen
`sions. The present invention, the description of Which is
`fully set forth beloW, solves the need in the art for such
`injectable compositions.
`
`SUMMARY OF THE INVENTION
`The present invention relates to injectable compositions
`having improved inj ectability, and to methods for the prepa
`ration of such injectable compositions. In one aspect of the
`invention, a composition suitable for injection through a
`
`LUYE1001
`IPR of Patent No. 6,667,061
`
`
`
`US 6,667,061 B2
`
`3
`needle into a host is provided. The composition comprises
`microparticles having a polymeric binder, With a mass
`median diameter of at least about 10 pm. The composition
`also includes an aqueous injection vehicle (the injection
`vehicle not being the aqueous injection vehicle that consists
`of 3% by volume sodium carboXymethyl cellulose, 1% by
`volume polysorbate 20, 0.9% by volume sodium chloride,
`and a remaining percentage by volume of Water). The
`microparticles are suspended in the injection vehicle at a
`concentration of greater than about 30 mg/ml to form a
`suspension, the ?uid phase of the suspension having a
`viscosity of at least 20 cp at 20° C. In other embodiments,
`the ?uid phase of the suspension has a viscosity at 20° C. of
`at least about 30 cp, 40 cp, 50 cp, and 60 cp. The compo
`sition may also comprise a viscosity enhancing agent, a
`density enhancing agent, a tonicity enhancing agent, and/or
`a Wetting agent. The composition can be administered to a
`host by injection.
`In another aspect of the present invention, a method of
`making a composition suitable for injection through a needle
`into a host is provided. The method comprises:
`(a) providing microparticles comprising a polymeric
`binder, said microparticles having a mass median diam
`eter of at least about 10 pm;
`(b) providing an aqueous injection vehicle having a
`viscosity of at least 20 cp at 20° C., Wherein said
`injection vehicle is not the aqueous vehicle consisting
`of 3% by volume sodium carboXymethyl cellulose, 1%
`by volume polysorbate 20, 0.9% by volume sodium
`chloride, and a remaining percentage by volume of
`Water; and
`(c) suspending the microparticles in the aqueous injection
`vehicle at a concentration of greater than about 30
`mg/ml to form a suspension.
`In a further aspect of the present invention, another
`method for preparing a composition suitable for injection
`through a needle into a host is provided. In such a method,
`dry microparticles are miXed With an aqueous injection
`vehicle to form a ?rst suspension. The ?rst suspension is
`miXed With a viscosity enhancing agent to form a second
`suspension. The viscosity enhancing agent increases the
`viscosity of the ?uid phase of the second suspension. The
`?rst suspension may be WithdraWn into a ?rst syringe, prior
`to miXing With the viscosity enhancing agent. The ?rst
`suspension may be miXed With the viscosity enhancing agent
`by coupling the ?rst syringe containing the ?rst suspension
`to a second syringe that contains the viscosity enhancing
`agent. The ?rst suspension and the viscosity enhancing agent
`are then repeatedly passed betWeen the ?rst and second
`syringes.
`In yet a further aspect of the present invention, a method
`for administering a composition to a host is provided. The
`method comprises:
`(a) miXing dry microparticles With an aqueous injection
`vehicle to form a ?rst suspension;
`(b) miXing the ?rst suspension With a viscosity enhancing
`agent to form a second suspension, Wherein the vis
`cosity enhancing agent increases the viscosity of the
`?uid phase of the second suspension; and
`(c) injecting the second suspension into the host.
`In still a further aspect of the present invention, another
`method for administering a composition to a host is pro
`vided. The method comprises:
`(a) miXing dry microparticles With an aqueous injection
`vehicle to form a suspension, Wherein the aqueous
`injection vehicle has a viscosity at 20° C. of less than
`about 60 cp;
`
`10
`
`15
`
`20
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`(b) changing the viscosity of the ?uid phase of the
`suspension;
`(c) WithdraWing the suspension into a syringe; and
`(d) injecting the suspension from the syringe into the host.
`In a further aspect of the invention, step (b) is carried out by
`changing the temperature of the ?uid phase of the suspen
`
`sion. In another aspect, step (c) is performed prior to step Step (b) may be carried out by adding a viscosity enhancing
`agent to the suspension in the syringe to thereby increase the
`viscosity of the ?uid phase of the suspension.
`In still a further aspect of the invention, a method for
`preparing a composition suitable for injection through a
`needle into a host is provided. The method comprises:
`(a) miXing dry microparticles With an aqueous injection
`vehicle that comprises a viscosity enhancing agent to
`form a suspension;
`(b) removing Water from the suspension; and
`(c) reconstituting the suspension With a quantity of sterile
`Water for injection to form an injectable suspension,
`Wherein the quantity of sterile Water for injection is
`suf?cient to achieve a viscosity of a ?uid phase of the
`injectable suspension that provides injectability of the
`composition through a needle ranging in diameter from
`18—22 gauge.
`Features and Advantages
`A feature of the present invention is that the injectable
`compositions can be used to inject varying types of
`microparticles, and varying types of active agents or other
`substances, into a host.
`A further feature of the present invention is that it alloWs
`microparticles to be Wetted to achieve a homogeneous
`suspension, While improving injectability into a host and
`reducing in vivo injectability failures.
`The present invention advantageously provides medically
`acceptable injectability rates for high concentration
`suspensions, and for suspensions having large particle siZe.
`The present invention also advantageously provides an
`ef?cient method of improving in vivo injectability Without
`introducing microbial contamination or compromising asep
`tic conditions.
`DETAILED DESCRIPTION OF THE
`PREFERRED EMBODIMENTS
`
`OvervieW
`The present invention relates to injectable compositions
`having improved inj ectability, and to methods for the prepa
`ration of such injectable compositions. The injectable com
`positions of the present invention overcome injectability
`problems, particularly injectability failures that occur upon
`injection into muscle or subcutaneous tissue. Such inject
`ability failures Will be referred to herein as “in vivo inject
`ability failures.” In vivo injectability failures often manifest
`themselves in the form of a plug at the tip of the needle, and
`occur immediately or shortly after injection has been initi
`ated. In vivo injectability failures are typically not predicted
`by laboratory or other in vitro testing.
`The inventors have unexpectedly discovered that inject
`ability is improved, and in vivo injectability failures signi?
`cantly and unexpectedly reduced, by increasing the viscosity
`of the ?uid phase of an injectable suspension. This is in
`contrast to conventional teachings that an increase in the
`viscosity hinders injectability and syringeability.
`Viscous vehicles, hoWever, are not optimal for preparing
`homogeneous suspensions of microparticles because of the
`relative inability of viscous vehicles to penetrate and Wet out
`a mass of dry particles. Suspensions prepared With viscous
`vehicles are prone to clump irreversibly. Consequently, such
`
`LUYE1001
`IPR of Patent No. 6,667,061
`
`
`
`US 6,667,061 B2
`
`5
`suspensions are not injectable via needles of medically
`acceptable siZe. A further disadvantage of viscous suspen
`sions is the lack of ease of transferring such suspensions
`from the vial or container used to prepare the suspension to
`the syringe used for injection.
`The present invention also solves the additional problems
`that arise from use of a viscous injection vehicle. In accor
`dance With the present invention, microparticles are sus
`pended in an injection vehicle having suitable Wetting
`characteristics. The viscosity of the ?uid phase of the
`injectable suspension is increased prior to injecting the
`suspension in order to improve injectability, and to reduce in
`vivo injectability failures.
`To ensure clarity of the description that folloWs, the
`folloWing de?nitions are provided. By “microparticles” or
`“microspheres” is meant particles that contain an active
`agent or other substance dispersed or dissolved Within a
`polymer that serves as a matrix or binder of the particle. The
`polymer is preferably biodegradable and biocompatible. By
`“biodegradable” is meant a material that should degrade by
`bodily processes to products readily disposable by the body
`and should not accumulate in the body. The products of the
`biodegradation should also be biocompatible With the body.
`By “biocompatible” is meant not toxic to the body, is
`pharmaceutically acceptable, is not carcinogenic, and does
`not signi?cantly induce in?ammation in body tissues. As
`used herein, “body” preferably refers to the human body, but
`it should be understood that body can also refer to a
`non-human animal body. By “Weight %” or “% by Weight”
`is meant parts by Weight per hundred parts total Weight of
`microparticle. For example, 10 Wt. % active agent Would
`mean 10 parts active agent by Weight and 90 parts polymer
`by Weight. Unless otherWise indicated to the contrary, per
`centages (%) reported herein are by volume. By “controlled
`release microparticle” or “sustained release microparticle” is
`meant a microparticle from Which an active agent or other
`type of substance is released as a function of time. By “mass
`median diameter” is meant the diameter at Which half of the
`distribution (volume percent) has a larger diameter and half
`has a smaller diameter.
`
`METHOD AND EXAMPLES
`
`The folloWing examples are provided to explain the
`invention, and to describe the materials and methods used in
`carrying out the invention. The examples are not intended to
`limit the invention in any manner.
`
`Example 1
`
`In vitro Sieve Test Study
`
`To evaluate in vivo injectability failures, an in vitro sieve
`test study Was conducted to assess and predict in vivo
`injectability, and to determine the key factors affecting
`injectability. The folloWing factors Were investigated during
`the in vitro sieve test study: injection vehicle formulation;
`microparticle morphology; needle diameter; suspension
`concentration; and particle siZe as exhibited by sieve screen
`siZe used to screen the microparticles during the manufac
`turing process.
`Three batches of risperidone microparticles Were manu
`factured at a 125 gm scale using a process substantially the
`same as that disclosed in US. Pat. No. 5,792,477, the
`entirety of Which is incorporated herein by reference (see,
`for example, Example 1 in US. Pat. No. 5,792,477). Three
`batches of risperidone microparticles Were manufactured at
`a 1 Kg scale using the process described beloW in Example
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`7. All batches had similar particle siZes (ranging from a
`Mass Median Diameter of 91 pm to 121 pm) based on
`Hyac-Royco analysis of representative bulk material sieved
`through a 180 pm sieve screen. A 160 mg or 320 mg quantity
`of the microparticles (equivalent to a 50 or 100 mg dose of
`the risperidone active agent) Was transferred, using a manual
`Perry poWder ?ller With a 5/16 inch ID barrel, into a 5 cc glass
`vial, and capped With a Te?on lined septum.
`TWo injection vehicles Were used in the in vitro sieve test
`study. The ?rst injection vehicle (“Formula 1”) Was an
`aqueous vehicle consisting of 1.5% by volume carboxym
`ethyl cellulose (CMC), 30% by volume sorbitol, and 0.2%
`by volume TWeen 20 (polysorbate 20). The viscosity of the
`?rst injection vehicle Was approximately 27 cp at 20° C. The
`second injection vehicle (“Formula 2”) Was an aqueous
`vehicle consisting of 0.75% by volume CMC, 15% by
`volume sorbitol, and 0.2% by volume TWeen 20
`(polysorbate 20). The viscosity of the second injection
`vehicle Was approximately 7 cp at 20° C.
`The microparticle suspension Was prepared as folloWs.
`The injection vehicle Was aspirated into a 5 cc syringe
`through a needle. The vehicle Was then injected into the
`glass vial containing the microparticles, and the needle Was
`removed. The glass vial Was then rolled betWeen the palms
`until the microparticles Were completely suspended,
`approximately one minute. The needle Was reinserted into
`the vial so that the bevel of the needle Was just through the
`septum With the opening facing toWard the vial bottom. The
`vial Was inverted and the suspension Was WithdraWn. The
`syringe Was rotated 180° around its axis, and the remaining
`suspension Was aspirated into the syringe.
`Sieve screens With mesh opening siZes of 180, 212, 250,
`300, 355, and 425 pm Were used. The bevel of the syringe
`needle Was placed on the mesh of the sieve screen so that the
`bevel Was in full contact With the mesh. The needle Was
`oriented so the opening of the needle Was ?ush against the
`mesh of the screen. This prevented the mesh from entering
`the bevel, While maintaining the required restrictive area.
`The suspension Was tried on the smallest sieve mesh ?rst
`(highest screen resistance). If the suspension fouled the
`needle on this sieve mesh, the needle Was unclogged by
`retracting the plunger of the syringe, depressing the plunger
`While the syringe Was in the upWard position, and passing an
`aliquot of suspension through the needle. The injection
`process Was tried again using the next greater mesh siZe, and
`repeated until the suspension Was successfully injected. All
`preparations Were done in triplicate.
`A three-factor Box-Behnken statistical designed experi
`ment Was constructed to evaluate the folloWing independent
`variables: manufacturing bulk sieve siZe (125, 150, and 180
`pm); needle ID (19 TW, 20 RW, and 22 RW gauge—ID of
`19 TW (thin Wall) equivalent to 18 RW (regular Wall)); and
`suspension concentration (0.074, 0.096, and 0.138 W/W—
`corresponds to approximately 300 mg microparticle dose
`diluted With 4, 3, and 2 cc, respectively, of injection vehicle).
`The folloWing scoring system Was used:
`
`Score
`
`Result
`
`Needle Block
`Passes through a 425 ,um screen
`Passes through a 355 ,um screen
`Passes through a 300 ,um screen
`Passes through a 250 ,um screen
`Passes through a 212 ,um screen
`
`LUYE1001
`IPR of Patent No. 6,667,061
`
`
`
`7
`Table 1 below shows the score obtained for screen resis
`tance tests using this scoring system for the 1 Kg and the 125
`gm batches for each of the injection vehicles tested.
`
`8
`doses of TelaZole and XylaZine and With halothane if
`needed. Injection sites Were shaved and cleansed With beta
`dine sWabs prior to microparticle administration.
`
`US 6,667,061 B2
`
`TABLE 1
`
`Mean Score
`
`Mfg Bulk Sieve Size
`
`n
`
`Formula 2 = 7 cp
`
`Formula 1 = 27 cp
`
`1 Kg Batches
`
`<180
`<125
`125 Gm Batches
`
`<180
`<150
`<125
`
`9
`9
`
`6
`6
`6
`
`2.3
`3.4
`
`1.5
`3.0
`3.0
`
`2.3
`3.7
`
`2.0
`2.8
`2.5
`
`As shoWn in Table 1, the screen resistance tests shoWed no
`signi?cant difference betWeen the tWo injection vehicles
`tested. Variations in suspension concentration and injection
`vehicle viscosity shoWed little to no effect. For the 1 Kg
`Batches, the mean scores Were identical for the <180 manu
`facturing bulk sieve siZe, even though the viscosity of the
`Formula 1 injection vehicle Was approximately 27 cp, and
`the viscosity of the Formula 2 injection vehicle Was signi?
`cantly less, approximately 7 cp. The scores for the other 1
`Kg Batch and for the 125 Gm Batches varied modestly (0.2
`to 0.5) betWeen the tWo injection vehicles, thereby indicat
`ing that the injection vehicle viscosity had little effect. The
`tests conducted during the in vitro sieve test study shoW that
`in vitro injectability is strongly controlled by microparticle
`morphology and siZe. Needle gauge had a more modest
`effect. As Will be discussed in more detail beloW, in vivo data
`supported the responses of microparticle morphology, siZe,
`and suspension concentration, but contradicted the effect of
`injection vehicle viscosity. Particularly, the in vivo studies
`shoWed a dramatic improvement in injectability With
`increased injection vehicle viscosity.
`In vivo Injectability
`
`Example 2
`
`Pig Study
`
`The injectability of risperidone microparticles Was evalu
`ated in Yorkshire Weanling pigs. The study revealed that the
`IM injectability of risperidone microparticles is dependent
`upon injection vehicle viscosity and microparticle siZe.
`Reducing the injection vehicle viscosity led to a higher rate
`of injection failures due to needle clogging.
`Risperidone microparticles Were manufactured at the 125
`gm scale in the same manner noted above for the in vitro
`sieve test study. The microparticles Were siZed to <125 pm
`and <150 pm using USA Standard Testing Sieves Nos. 120
`and 100, respectively. The same tWo injection vehicles
`(Formula 1 and Formula 2) described above for the in vitro
`sieve test study Were used in the pig study. 19 gauge TW><1.5
`inch hypodermic needles (Becton-Dickinson Precision
`glide® catalog number 305187) and 3 cc hypodermic
`syringes (Becton-Dickinson catalog number 309585) Were
`used.
`The injection experiments Were conducted in male and
`female Yorkshire Weanling pigs approximately 6 Weeks in
`age (10—15 kg). The animals Were anesthetiZed With loW
`
`Injections to the hind quarters Were administered to the
`biceps femoris in the upper hind limb. Injection sites in the
`legs Were to the super?cial digital ?exor muscles in the
`forelimb, and to the cranial tibial muscle in the hindlimb.
`Microparticles and injection vehicles Were equilibrated to
`ambient temperature for at least 30 minutes. Using a 3 ml
`syringe equipped With a 1.5 inch 19 gauge thin Wall needle,
`the prescribed volume of injection vehicle Was WithdraWn
`into the syringe, and injected into the vial containing the
`microparticles. The microparticles Were suspended in the
`injection vehicle by orienting the vial horiZontally and
`rolling it betWeen the palms of the operator’s hands. This
`Was done Without removing the needle/syringe from the
`septum. The time required to fully suspend the micropar
`ticles Was approximately one minute.
`
`The suspended microparticles Were then WithdraWn into
`the same needle/syringe and injected. FolloWing insertion of
`the needle and prior to injection of the suspension, the
`syringe plunger Was WithdraWn slightly to con?rm that the
`needle Was located in the extravascular space. The time
`interval betWeen aspiration of the suspension and injection
`Was usually less than one minute. Injection regions Were
`evaluated to pinpoint the site of microparticle deposition and
`to assess the distribution of microparticles in the tissue.
`
`Table 2 beloW shoWs the effect on injectability as a
`function of injection vehicle viscosity, injection site, and
`microparticle concentration. A vehicle viscosity of “high”
`refers to the injection vehicle of Formula 1 described above,
`having a viscosity of approximately 27 cp at 20° C.
`Similarly, a vehicle viscosity of “loW” refers to the injection
`vehicle of Formula 2 described above, having a viscosity of
`approximately 7 cp at 20° C. The siZe of the microparticles
`for the results shoWn in Table 2 is 180 pm.
`
`TABLE 2
`
`Vehicle
`Viscosity
`
`Microparticle
`Dose
`
`Volume
`
`Site
`
`Failure rate
`
`High
`High
`LoW
`High
`
`160 mg
`160 mg
`160 mg
`320 mg
`
`1 mL
`1 mL
`1 mL
`1 mL
`
`Hind quarter
`Leg
`Hind quarter
`Hind quarter
`
`0/10
`1/8
`4/7
`0/4
`
`As can be seen from Table 2, increased failure rates Were
`observed With the loWer viscosity injection vehicle (4 fail
`ures With 7 injections), and When the injection site Was in the
`leg (1 failure per 8 injections). The increased failure rate due
`to reduced viscosity Was statistically signi?cant at the 1%
`level (Fisher Exact